Left Gastric Artery Embolization in Obese, Prediabetic Patients: A Pilot Study

J Vasc Interv Radiol. 2019 Jun;30(6):790-796. doi: 10.1016/j.jvir.2019.02.010. Epub 2019 Apr 27.

Abstract

Purpose: To evaluate the effect of left gastric artery embolization (LGAE) on glycated hemoglobin (HbA1c) in a prospective obese, prediabetic cohort.

Materials and methods: This prospective pilot study included 10 obese, prediabetic patients (7 females and 3 males; mean age 37.5 ± 8.8 years; range 28-51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed using a paired sample t test.

Results: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively. Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant positive correlation was found between BMI and HbA1c after the procedure (r = 0.91, P = .0002).

Conclusions: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabetic patients.

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Body Mass Index
  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Female
  • Gastric Artery* / diagnostic imaging
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / diagnosis
  • Obesity / physiopathology
  • Obesity / therapy*
  • Pilot Projects
  • Prediabetic State / blood
  • Prediabetic State / diagnosis
  • Prediabetic State / physiopathology
  • Prediabetic State / therapy*
  • Prospective Studies
  • Radiography, Interventional
  • Time Factors
  • Treatment Outcome
  • Weight Loss*

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human